<?xml version="1.0" encoding="UTF-8"?>
<p>Two other potential mAbs are Leronlimab and Ibalizumab, both of which bind specifically to the Câ€“C chemokine receptor type 5 (CCR5). A phase II clinical trial assessing leronlimab in COVID-19 patients with respiratory complications was registered in April 2020 [
 <xref rid="B206-ijms-21-05559" ref-type="bibr">206</xref>]. Ibalizumab is non-immunosuppressive, FDA approved for the treatment of multidrug-resistant HIV in 2018 [
 <xref rid="B207-ijms-21-05559" ref-type="bibr">207</xref>] and may be considered as a co-treatment agent for COVID-19 in the future.
</p>
